HOME >> BIOLOGY >> NEWS
Clinical trial shows timing of chemotherapy improves survival in breast cancer

New York, December 12, 2002 New research shows that giving doses of chemotherapy more frequently in time, leads to a significant improvement in survival with no increase in toxicity in women with node-positive breast cancer. The study, coordinated by the Cancer and Leukemia Group B (CALGB) for the National Cancer Institute's Breast Intergroup, found a 31 percent decrease in the death rate with more frequent chemotherapy administration, called "dose dense," compared to conventional treatment. The findings will be presented today at the 25th Annual San Antonio Breast Cancer Symposium.

"Since breast cancer is so common, and adjuvant drug therapy has already been found to be so effective, a way to make that treatment 31 percent more effective could potentially save thousands of lives per year in the United States alone," said Larry Norton, MD, Head of the Division of Solid Tumor Oncology at Memorial Sloan-Kettering Cancer Center, and senior author of the study.

A mathematical model called the Norton-Simon hypothesis formed the basis for the concept of dose density and another concept tested in this study, sequential therapy. The model, developed by Dr. Norton, and Richard Simon of the National Cancer Institute, was used to address the question: "Is it better to use a higher dose of a drug less often or a lower dose more frequently?" According to Dr. Norton, the answer depended upon the efficacy of the drugs and the pattern of growth of the disease, and could not be answered without a mathematical understanding of the underlying biology.

The study enrolled 2005 women with primary breast cancer that had spread to the lymph nodes, and with no other metastases. They were randomized post-operatively to one of four treatments. Two groups of patients were randomized to receive doxorubicin (A for Adriamycin), paclitaxel (T for Taxol), and cyclophosphamide (C for Cytoxan) sequentially, i.e., one at a time, in two- or three-week c
'"/>

Contact: Christine Hickey
media@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
12-Dec-2002


Page: 1 2 3

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... , Europe,s most prestigious ... Office to present a video retrospective of the most exciting and ... Christofer Toumazou and Sophie Wilson   A ... Award   Starting on 22 January 2015 on   http://www.epo.org/european-inventor ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... focused on advanced wound care, announces that AMNIOEXCEL® ... have been added to the Premier, Inc. Regenerative ... opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
Cached News: